Section Arrow
AKBA.NASDAQ
- Akebia Therapeutics
Quotes are at least 15-min delayed:2026/02/10 00:47 EST
Regular Hours
Last
 1.5
+0.11 (+7.91%)
Day High 
1.51 
Prev. Close
1.39 
1-M High
1.565 
Volume 
3.89M 
Bid
1.47
Ask
1.49
Day Low
1.33 
Open
1.37 
1-M Low
1.3 
Market Cap 
368.86M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.42 
20-SMA 1.4 
50-SMA 1.52 
52-W High 4.0787 
52-W Low 1.3 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.08/0.04
Enterprise Value
411.10M
Balance Sheet
Book Value Per Share
0.16
Cash Flow
Cash Flow Yield
0.09
Income Statement
Total Revenue
160.18M
Operating Revenue Per Share
0.76
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
HIMSHims & Hers Health19.33-3.69-16.03%36.28PE
VTRSViatris15.56+0.98+6.72%227.2PE
BFRIBiofrontera0.8103-0.0107-1.30%0.74PE
CGCCanopy Growth Corp1.09-0.01-0.91%-- 
HLNHaleon plc10.88-0.1-0.91%23.79PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.